Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 7/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461547 | 0.84 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| SCHEMBL16291590 | 0.84 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| SCHEMBL15165328 | 0.84 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| Hydrochloric Acid SCHEMBL20211268 | 0.83 | SCN4A (0.44) | SLC6A2SCN4ADPP4F2GBA1 | |
| Hydrochloric Acid SCHEMBL20211265 | 0.83 | SCN4A (0.44) | SLC6A2SCN4ADPP4F2GBA1 | |
| SCHEMBL5046280 | 0.82 | TAAR1 (0.48) | SLC6A2TAAR1DPP4 | |
| SCHEMBL11409559 | 0.82 | TACR1 (0.43) | TAAR1SCN4A | |
| SCHEMBL17724556 | 0.81 | SCN4A (0.42) | SLC6A2SCN4ADPP4F2 | |
| SCHEMBL434164 | 0.81 | SCN4A (0.42) | SLC6A2SCN4ADPP4F2 | |
| Bromide SCHEMBL29799767 | 0.80 | TAAR1 (0.46) | SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
| US-6953797-B2 | Use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-10-11 | — | — | US | disclosed |
| EP-1263718-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | CYP1A1, CYP1A2, CYP2E1 | SLC6A2 1769/4885TAAR1 767/4885SCN4A 1664/4885 |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | SLC6A2 3058/4885TAAR1 4730/4885SCN4A 2098/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | SLC6A2 3058/4885TAAR1 4730/4885SCN4A 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.